This study aimed to establish a practical and convenient method of predicting intestinal availability (F g ) in humans for highly permeable compounds at the drug discovery stage, with a focus on CYP3A4-mediated metabolism. We constructed a "simplified F g model," described using only metabolic parameters, assuming that passive diffusion is dominant when permeability is high and that the effect of transporters in epithelial cells is negligible. Five substrates for CYP3A4 (alprazolam, amlodipine, clonazepam, midazolam, and nifedipine) and four for both CYP3A4 and P-glycoprotein (P-gp) (nicardipine, quinidine, tacrolimus, and verapamil) were used as model compounds. Observed fraction of drug absorbed (F a F g ) values for these compounds were calculated from in vivo pharmacokinetic (PK) parameters, whereas in vitro intestinal intrinsic clearance (CL int,intestine ) was determined using human intestinal microsomes. The CL int,intestine for the model compounds corrected with that of midazolam was defined as CL m,index and incorporated into a simplified F g model with empirical scaling factor. Regardless of whether the compound was a P-gp substrate, the F a F g could be reasonably fitted by the simplified F g model, and the value of the empirical scaling factor was well estimated. These results suggest that the effects of P-gp on F a and F g are substantially minor, at least in the case of highly permeable compounds. Furthermore, liver intrinsic clearance (CL int,liver ) can be used as a surrogate index of intestinal metabolism based on the relationship between CL int,liver and CL m,index . F g can be easily predicted using a simplified F g model with the empirical scaling factor, enabling more confident selection of drug candidates with desirable PK profiles in humans.
Given the substantial time and cost associated with drug discovery and development, increasing importance has been placed on the prediction of pharmacokinetics (PK) in humans of drug candidates at the discovery stage to avoid later termination of development because of an undesirable PK profile.
Bioavailability (F) of an orally administered drug, which is the fraction of drug reaching systemic blood circulation, is expressed as the product of the fraction of the dose that enters the enterocyte (F a ), intestinal availability (F g ), and hepatic availability (F h ). Therefore, to effectively pass into systemic blood circulation, orally administered drugs must not only have high solubility and permeability in the gastrointestinal tract but also be stable against metabolizing enzymes in the gastrointestinal tract and liver.
At the drug discovery stage, compounds selected as drug candidates using high-throughput screening typically are those with high permeability because intestinal permeability is one of the most important factors in determining the F of orally administered drugs. Although P-glycoprotein (P-gp) is highly expressed in intestinal epithelial cells and has the potential to reduce drug absorption, the effect on drug absorption is not quantitatively as important as suggested, particularly for highly permeable compounds (Chiou et al., 2001; Lin, 2004; Cao et al., 2005) . Therefore, for highly permeable compounds, a relatively high F a can be expected when dissolution in the gastrointestinal tract is not the rate-limiting step.
CYP3A subfamily and P-gp are present in high levels in human intestinal epithelial cells as a metabolizing enzyme and an efflux transporter, respectively. Benet et al. (1999) proposed that the synergistic effects of CYP3A4-mediated metabolism and P-gp-mediated efflux in epithelial cells may result in an unexpectedly high first-pass metabolism in the intestine because of the overlapping substrate specificities of these proteins. Ito et al. (1999) constructed a theoretical model for F a F g that took into consideration the integrated process of permeability and metabolism in epithelial cells (eq. 1):
where PS inf is the apparent influx clearance from the lumen to epithelial cells, PS eff is the efflux clearance from cells to the lumen, CL ab is the absorption clearance from cells to blood, CL m is the metabolic clearance in cells, and Q is luminal flow rate. However, precise estimation of several parameters described in the theoretical model is difficult; therefore, application of the model has not been reported. Yang et al. (2007) constructed a "Q gut model" for predicting F g (eqs. 2 and 3):
where CL perm is the clearance defining permeability through the enterocyte, Q villi is villous blood flow, fu G is the fraction of unbound drug in the enterocyte, and Q gut is a hybrid parameter of CL perm and Q villi . In their report, assuming fu G to be unity and a Q villi value of 18 l/h, the accuracy in predicting F g was better than that of the "well stirred" gut model. Therefore, if the values of CL perm and intestinal intrinsic clearance (CL int,intestine ) can be estimated precisely and easily, the Q gut model may be useful in predicting F g at the drug discovery stage.
In the present study, we aimed to establish a more practical and convenient method for predicting F g by simplifying the theoretical model under conditions of high permeability. We focused on CYP3A4-mediated metabolism and examined CL int,intestine of five model compounds for CYP3A4 substrates (alprazolam, amlodipine, clonazepam, midazolam, and nifedipine) and four model compounds for both CYP3A4 and P-gp substrates (nicardipine, quinidine, tacrolimus, and verapamil). The obtained CL int,intestine were corrected using the CL int,intestine of midazolam (reference compound). These corrected values, defined as CL m,index , were incorporated into the simplified model. We examined whether F g values for highly permeable compounds can be explained satisfactorily by the simplified model. In addition, the relationship between CL m,index and CL int,liver was examined for 35 compounds, and a reliable procedure for predicting F g was proposed.
Materials and Methods
Materials. All the compounds except midazolam and tacrolimus were purchased from either Sigma-Aldrich (St. Louis, MO) or Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Midazolam, tacrolimus, and in-house compounds were provided by Astellas Pharma Inc. (Tokyo, Japan). Pooled human intestinal microsomes (HIMs) were purchased from XenoTech, LLC (Lenexa, KS), and individual HIMs were purchased from KAC Co., Ltd. (Kyoto, Japan). Pooled human liver microsomes (HLMs) were purchased from XenoTech, LLC. All the other chemicals and reagents were of analytical grade and purchased from commercial sources.
Permeability Study Using Artificial Membrane. Parallel artificial membrane permeability assays (PAMPAs) conducted in this study used the PAMPA Evolution from pION Inc. (Woburn, MA). In a PAMPA, a "sandwich" is formed from a 96-well microtiter plate ( pION Inc.) and a 96-well filter plate (polyvinylidene difluoride; Millipore Corporation, Billerica, MA), so that each composite well is divided into two chambers, with a donor at the bottom and an acceptor at the top, separated by a 125-m-thick microfilter disc (0.45-m pores) coated with a 20% (w/v) dodecane solution of a lecithin mixture ( pION Inc.). Drug samples were introduced via a 10 mM dimethyl sulfoxide (DMSO) stock solution in a 96-well polypropylene microtiter plate. The robotic liquid handling system draws a 5-l aliquot of the DMSO stock solution and mixes it into an aqueous buffer solution of 10% (v/v) DMSO to attain a final typical sample concentration of 50 M. The drug solutions were filtered using a 96-well filter plate (polyvinylidene fluoride; Corning Life Sciences, Lowell, MA) and added to the donor compartments. The donor solution was adjusted to pH 6.5 (NaOH-treated universal buffer; pION Inc.), whereas the acceptor solution had a pH of 7.4 ( pION Inc.). The plates were sandwiched together and incubated at 25°C for 2 h in a humidity-saturated atmosphere. After incubation, the sandwiched plates were separated, and both the donor and acceptor compartments were assayed for the amount of material present by comparison with the UV spectrum (270 -400 nm) obtained from reference standards. Mass balance was used to determine the amount of material remaining in the membrane barrier. The apparent permeability coefficient (P app ) was calculated using PAMPA Evolution software ( pION Inc.).
In Vitro Metabolism Study in HIMs. CL int,intestine was calculated from the substrate disappearance rate in HIMs. Each compound was incubated with a reaction mixture (1000 l) consisting of human intestinal microsomal protein in 100 mM potassium phosphate buffer, pH 7.4, and 0.1 mM EDTA. After preincubation for 5 min at 37°C, the enzyme reaction was initiated by adding 100 l of 10 mM NADPH. The final concentration of each compound was 0.2 M. The microsomal concentration used was 0.2 mg/ml except nicardipine, with the concentration of 0.02 mg/ml. The final concentration of the organic solvent (acetonitrile) in the reaction mixture was 0.5% (v/v) . For all the compounds except tacrolimus and cyclosporine, 100 l of the reaction mixture was moved into 200 l of acetonitrile containing internal standard (diazepam, 100 ng/ml) at appropriate time points for stopping the reaction. The reaction mixture was then centrifuged at 10,000g for 5 min, and 10 l of the aliquot was injected into a liquid chromatography/tandem mass spectrometry (LC/MS/MS) system. With regard to tacrolimus, 100 l of the reaction mixture was moved into 100 l of acetonitrile containing internal standard (ascomycin, 100 ng/ml) for stopping the reaction, and 500 l of 0.01 M ammonium acetate buffer, pH 7.5, and 4.5 ml of tert-butyl methyl ether were added. The mixture was shaken for 20 s and centrifuged at 1870g for 10 min at 4°C. Four milliliters of the organic layer was evaporated to dryness at 40°C under a stream of nitrogen. The residue was dissolved with 200 l of ammonium acetate (2 mM) in water with 75% methanol, and 10 l of the aliquot was injected into LC/MS/MS. With regard to cyclosporine, 100 l of the reaction mixture was moved into 100 l of acetonitrile containing the internal standard [in-house compound (derivative of cyclosporine), 100 ng/ml] to stop the reaction, and 500 l of distilled water and 4.5 ml of tert-butyl methyl ether were added. The mixture was shaken for 20 s and centrifuged at 1870g for 10 min at 4°C. Four milliliters of the organic layer was evaporated to dryness at 40°C under a stream of nitrogen. The residue was then dissolved with 200 l of ammonium acetate (10 mM) in water with 90% methanol, and 10 l of the aliquot was injected into LC/MS/MS.
Because the activity of cytochrome P450 (P450) enzymes in HIMs depends on the preparation method (mucosal scraping and enterocyte elution) (Galetin and Houston, 2006) , the use of absolute value of CL int,intestine for F g prediction is somewhat problematic. Therefore, in the present study, CL int,intestine , expressed as milliliters per minute per milligram of microsomal protein, was corrected for each compound with that of midazolam using eq. 4. This corrected value was defined as CL m,index . The CL m,index values were used for metabolic parameter in intestine.
In Vitro Metabolism Study in HLMs. CL int,liver was calculated from the substrate disappearance rate in HLMs. For nicardipine and felodipine, the microsomal concentrations used were 0.02 and 0.05 mg/ml, respectively, whereas a concentration of 0.2 mg/ml was used for the remaining commercial compounds. For in-house compounds, the concentrations used ranged from 0.02 to 0.2 mg/ml. The other experimental conditions and sample preparation
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Analytical Method. The compounds were measured by LC/MS/MS using a Quattro Ultima (Waters, Milford, MA) with an Alliance 2695 separation module (Waters). Multiple-reaction monitoring mode was used to monitor ions as follows (precursor ion/product ion): alprazolam ( With regard to alprazolam, amlodipine, clonazepam, nicardipine, and felodipine, samples were injected into an XTerra MC C18 column (3.5 m, 4.6 ϫ 50 mm; Waters) warmed to 40°C. Elution was conducted with 0.1% formic acid in water/acetonitrile (40:60) at a flow rate of 0.3 ml/min. With regard to midazolam, nifedipine, quinidine, verapamil, amitriptyline, propafenone, propranolol, and timolol, samples were injected into an Ascentis RP-Amide column (3 m, 3 ϫ 30 mm; Supelco, Bellefonte, PA) warmed to 50°C. Elution was conducted at a flow rate of 0.5 ml/min by a linear gradient with the mobile phase, which consisted of 20 mM ammonium acetate in water with 10% acetonitrile (A) and 20 mM ammonium acetate in water with 90% acetonitrile (B). Except for timolol, gradient conditions were as follows: at 0, 0.5, 1, 3, 3.1, and 4 min, B% was 0, 0, 70, 70, 0, and 0, respectively. For timolol, the gradient condition was as follows: at 0, 0.5, 1, 3, 3.1, and 4.5 min, B% was 0, 0, 70, 70, 0, and 0, respectively. With regard to tacrolimus, samples were injected into an XTerra MC C18 column (3.5 m, 4.6 ϫ 50 mm; Waters) warmed to 55°C. Elution was conducted at a flow rate of 0.4 ml/min with 2 mM ammonium acetate in water/2 mM ammonium acetate in methanol with 0.1% formic acid (20:80). With regard to cyclosporine, samples were injected into an XTerra MC C18 column (5 m, 2.1 ϫ 50 mm; Waters) warmed to 40°C. Elution was conducted at a flow rate of 0.2 ml/min with 10 mM ammonium acetate in water/methanol (10:90).
Calculation of F a F g in Humans. F a F g in humans was calculated using eqs. 5 through 7 as follows:
where CL h is hepatic clearance, CL tot is total body clearance, CL r is renal clearance, and Q h is hepatic blood flow in humans. Because the calculation of F a F g depends on Q h , three different reference values (17.1, 20.7, and 25.5 ml/min/kg) were used for Q h (Davies and Morris, 1993; Kato et al., 2003) , and the PK parameters were derived from the literature. When PK parameters were obtained from more than one reference, the mean values were used. When CL tot was obtained based on plasma concentration, it was converted to a blood-based value using the blood-to-plasma concentration ratio (R b ), which was obtained from the literature, or assumed to be unity if no value was available. Simplification of the Theoretical Model of F a F g . The following assumptions were made to simplify the theoretical model: Assumption 1. For highly permeable compounds, absorption is complete (F a ϭ 1) when dissolution in the gastrointestinal tract is not the rate-limiting step.
Equation 1 can thus be simplified to eq. 8 by Assumption 1.
According to eq. 8, F g value is determined by the balance of CL ab and CL m .
Assumption 2. The difference in CL ab values between highly permeable compounds is minor, and F g value is mainly determined by CL m .
Equation 8 can thus be simplified to eq. 9 by Assumption 2.
where A is the reciprocal value of CL ab and assumed to be treated as a constant value. Assumption 3. CL m is proportional to CL m,index . As shown in eq. 4, CL m,index is a metabolic parameter that has been corrected using reference compound (midazolam).
where SF is the scaling factor between CL m and CL m,index . Combining eqs. 9 and 10 gives eq. 11.
where ␣ is defined as the empirical scaling factor (eq. 12).
In the present study, eq. 11 is referred to as the simplified F g model. We examined whether F g values for highly permeable compounds can be satisfactorily explained using this simplified F g model.
Estimation of the Empirical Scaling Factor (␣) of Simplified F g Model. Alprazolam, amlodipine, clonazepam, midazolam, nifedipine, nicardipine, quinidine, tacrolimus, and verapamil were used to establish the simplified F g model. The value of ␣ was estimated from a fitting study between human F a F g and the CL m,index values of these model compounds using a nonlinear leastsquares method, MULTI (Yamaoka et al., 1981) .
Results
Initially, permeability of the model compounds (alprazolam, amlodipine, clonazepam, midazolam, nifedipine, nicardipine, quinidine, tacrolimus, and verapamil) was examined using an artificial membrane, and the values of P app,PAMPA were compared with those of 25 reference compounds having known F a in humans (Zhu et al., 2002) ( Table 1 ). Figure 1 shows the correlation of P app,PAMPA versus F a of the reference compounds. Based on the correlation, high F a can be expected when P app,PAMPA value is Ͼ1.0 ϫ 10 Ϫ6 cm/s. Because all the model compounds for CYP3A4 substrates showed high permeability (м7.0 ϫ 10 Ϫ6 cm/s), the F a F g values were assumed equal to F g values (F a ϭ 1). Table 2 shows the CL int,intestine of the model compounds obtained from in vitro metabolism study in HIMs. On comparison of CL int,intestine for four HIMs from different lots, an approximately 3-fold variation in the CL int,intestine was observed. CL int,intestine ranged from 0.167 to 0.534 ml/ min/mg for midazolam, 1.287 to 3.600 ml/min/mg for nicardipine, and 0.107 to 0.291 ml/min/mg for verapamil. However, similar values were observed after correction using eq. 4 to obtain CL m,index , with values ranging from 0.07 to 0.09 for amlodipine, 0.53 to 0.64 for nifedipine, 6.74 to 7.71 for nicardipine, 2.82 to 3.36 for tacrolimus, and 0.54 to 0.64 for verapamil. Therefore, in the present study, mean values of CL m,index were used for the fitting study with simplified F g model. Table 3 summarizes the PK parameters of the model compounds in humans and values for F a F g calculated from eqs. 5 through 7 under three different Q h conditions. 
PK parameters, F, F h , and F a F g of nine model compounds in humans
PK parameters were quoted from references as follows: alprazolam (Smith et al., 1984) ; amlodipine (Faulkner et al., 1986) ; clonazepam (Crevoisier et al., 2003) ; midazolam (Kupferschmidt et al., 1995; Thummel et al., 1996; Tsunoda et al., 1999) ; nifedipine (Holtbecker et al., 1996) ; nicardipine (Higuchi and Shiobara, 1980) ; quinidine (Greenblatt et al., 1977; Rakhit et al., 1984) ; tacrolimus (Floren et al., 1997; Möller et al., 1999); verapamil (McAllister and Kirsten, 1982; Eichelbaum et al., 1984 Figure 2 shows the relationship between the F a F g and CL m,index of the model compounds under three different Q h conditions. Regardless of whether the compound was a P-gp substrate, F a F g of the model compounds decreased as CL m,index increased, and reasonably good fits were obtained using simplified F g model, at least in the case of middle and high Q h conditions (20.7 and 25.5 ml/min/kg, respectively). The ␣ values obtained for the Q h conditions of 17.1, 20.1, and 25.5 ml/min/kg were 0.43, 0.64, and 1.13, respectively (Table 4) .
The observed F a F g and predicted F g for felodipine and cyclosporine, which are CYP3A4 substrates with high permeability and outside the model compounds used to construct the simplified F g model, are presented in Tables 5 and 6 . F g prediction was conducted using a simplified F g model with the ␣ values listed in Table 4 . For felodipine, extensive metabolism in HIMs was observed (CL m,index was 2.80), and the predicted F g ranged from 0.240 to 0.454. The predicted values were close to the observed F a F g values (0.222-0.291). In contrast, for cyclosporine, mild metabolism in HIMs was observed (CL m,index was 0.30), and the predicted F g ranged from 0.747 to 0.886. The predicted values were slightly higher than the observed F a F g values (0.567-0.684). Figure 3 shows the relationship between CL m,index and CL int,liver for 35 compounds containing the model compounds, additional 5 drug compounds (amitriptyline, felodipine, propafenone, propranolol, and timolol), and 21 in-house compounds. The results showed reasonably good correlation between these parameters; for example, when CL int,liver was Ͻ100 ml/min/kg, CL m,index of almost all the compounds was Ͻ0.2. On the other hand, when CL int,liver was Ͼ100 ml/min/kg, most CL m,index increased. Furthermore, when CL int,liver was Ͼ1000 ml/min/kg, CL m,index of all the compounds exceeded 1.0. However, some compounds had CL m,index Ͻ0.2 despite having a CL int,liver Ͼ100 ml/min/kg.
Discussion
The importance of the intestine on drug metabolism has been well recognized (Wacher et al., 2001) ; however, it is difficult to estimate precisely all the important factors for intestinal metabolism at the drug discovery stage. Rats, dogs, and monkeys have been widely used in the prediction of PK in humans at the drug discovery stage, and evaluation using rats has been particularly useful for satisfactorily predicting F a in humans (Zhao et al., 2003) . However, expression levels and patterns for metabolizing enzymes in intestine differ distinctly between the two species (Cao et al., 2006) . Furthermore, with regard to dogs, intestinal enzymes are generally less active than in humans (Prueksaritanont et al., 1996) , and although monkeys are genetically similar to humans, some drugs have shown remarkably lower F a F g in monkeys than in humans, possibly because of activity of metabolizing enzymes and efflux transporters being higher in monkey intestine than in human intestine (Takahashi et al., 2009; Akabane et al., 2010) . Therefore, these experimental animals are unsuitable for predicting F g in humans.
In the present study, we aimed to develop a practical and convenient method for predicting F g of highly permeable compounds using alprazolam; 2, amlodipine; 3, clonazepam; 4, midazolam; 5, nifedipine; 6, nicardipine; 7, quinidine; 8, tacrolimus; 9, verapamil. showed that, regardless of whether a compound was a P-gp substrate, F a F g of the model compounds decreased as the CL m,index increased, and the F a F g could be reasonably fitted using a simplified F g model ( Fig. 2 ; Table 4 ). If P-gp-mediated efflux has a significant impact on F a , and if synergistic effects of CYP3A4-mediated metabolism and P-gp-mediated efflux result in an unexpectedly low F g , F a F g of P-gp and non-P-gp substrates cannot be well fitted by the same curve obtained from the simplified F g model. This finding suggests that, at least for highly permeable compounds, the effect of P-gp on F a and the synergistic effects of CYP3A4 and P-gp on F g are substantially minor. Furthermore, to verify the reliability of the simplified F g model and ␣ values, F g prediction using simplified F g model was conducted for cyclosporine and felodipine, which are CYP3A4 substrates having high permeability (Tables 5 and 6 ). With regard to cyclosporine, the predicted F g value was slightly higher than the observed F a F g value. This discrepancy may be because of the dissolution characteristics of cyclosporine being sufficiently poor to cause low F a (Varma and Panchagnula, 2005) . With regard to felodipine, the predicted F g value was close to the observed F a F g value.
According to the Q gut model (Yang et al., 2007) , when permeability is high (CL perm Ͼ ϾQ villi ), eq. 2 can be transformed into eq. 13.
Provided the fu G value does not differ significantly among compounds, the F g value can be determined using only the metabolic parameter as the simplified F g model. This may explain why the simplified F g model was acceptable for predicting F g of highly permeable compounds.
However, for compounds with low permeability, the simplified F g model with ␣ estimated here may actually overestimate the observed F g . Residence time in epithelial cells for these low-permeability compounds may be longer than that of compounds with high permeability in the absorption process; thus, these compounds may have greater exposure to metabolizing enzymes within cells than more permeable compounds. Furthermore, according to the Q gut model (Yang et al., 2007) , when permeability is low (Q villi Ͼ ϾCL perm ), eq. 2 can be transformed into eq. 14. F g values for low-permeability compounds are determined by the balance of the permeability and metabolic parameter.
In the present study, we examined the relationship between CL m,index and CL int,liver for 35 compounds (Fig. 3) . Although results showed reasonably good correlation between these parameters, several compounds had CL m,index Ͻ0.2 despite having a CL int,liver Ͼ100 ml/min/kg. For example, whereas the model compounds for CYP3A4 substrates showed good correlation, propafenone, which is mainly metabolized by CYP2D6 (Dilger et al., 2000) , had CL m,index Ͻ0.2 despite having a CL int,liver of approximately 700 ml/min/kg. Furthermore, in-house compound A, which is mainly metabolized by CYP1A2 and CYP2D6, had a CL m,index of 0.01 despite having a CL int,liver of approximately 600 ml/min/kg. Although Galetin and Houston (2006) reported that the rank order of CL int values for CYP3A4, CYP2C9, CYP2C19, and CYP2D6 substrates was consistent between HLMs and HIMs, Paine et al. (2006) reported minimal contribution of CYP2D6 for intestinal metabolism. For example, the CL int value for metoprolol, a substrate for CYP2D6, was much lower in HIMs compared with HLMs (0.7 versus 19.7 l/min/mg). Furthermore, Kato et al. (2003) reported that F a F g values of CYP3A4 substrates, but not non-CYP3A4 substrates, were reduced when CL int,liver exceeded 100 ml/min/kg. Therefore, these previous findings suggest that metabolism in the intestine is probably minor for non-CYP3A4 substrates, even if metabolism in the liver is extensive. To obtain a more reliable prediction of F g , the value of CL m,index should be used rather than CL int,liver .
Based on the results, we proposed a reliable procedure for predicting F g in humans at the drug discovery stage. When CL int,liver of candidate compound is Ͼ100 ml/min/kg, CL m,index is typically Ͼ0.2, which results in a predicted F g of Ͻ0.814 when using a high ␣ (1.13); therefore, an in vitro metabolism study in HIMs should be performed to predict F g from the simplified F g model. To avoid underestimating F g values of drug candidates, the use of a high ␣ value (1.13) may be desirable at the drug discovery stage.
Although the present study focused on CYP3A4-mediated intestinal metabolism, conjugate enzymes such as UDP-glucuronyltransferase and sulfotransferase have also been found to be expressed in human intestine (Glatt et al., 2001; Cao et al., 2006) . In fact, the intestinal conjugative metabolism exerts a measurable impact on F in humans (Mizuma et al., 2005) . If values of F g in humans of substrates for conjugate enzymes can be fully compiled, estimation of empirical scaling factor related to conjugation may be possible from the simplified F g model, as in CYP3A4 substrates. PK parameters were quoted from reference as follows: cyclosporine (Gupta et al., 1990) ; felodipine (Hardman et al., 1996) . 
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In conclusion, we developed a practical and convenient method for predicting F g of highly permeable compounds from a simplified F g model and the results of an in vitro metabolism study in HIMs, focusing on CYP3A4-mediated metabolism. Using this method, F g can be easily predicted at the drug discovery stage, enabling more confident selection of drug candidates with desirable PK profiles in humans. alprazolam; 2, amlodipine; 3, clonazepam; 4, midazolam; 5, nifedipine; 6, nicardipine; 7, quinidine; 8, tacrolimus; 9, verapamil; 10, amitriptyline; 11, felodipine; 12, propafenone; 13, propranolol; 14, timolol. 1236 KADONO ET AL.
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